Murabutide
Also known as: 2‑(N‑acetyl‑β‑D‑glucosaminyl)‑L‑alanyl‑D‑isoglutamine, Immuno-Medics MDP analogue, MDP analog, MDP-butyl ester, Murabutide, N-acetylmuramyl-L-alanyl-D-glutamine n-butyl ester
Source Murabutide at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Murabutide is a synthetic muramyl dipeptide analogue that acts as an immunostimulant via NOD2 activation. It has been studied as a vaccine adjuvant and in oncology/infectious disease trials but is not approved for clinical use.
Mechanism of Action
Activates intracellular NOD2 receptor, leading to NF-κB activation and production of pro‑inflammatory cytokines (IL‑1β, TNF‑α, IL‑6).
Routes of Administration
Goals & Uses
- Vaccine adjuvantVaccinologyModerate
- Cancer adjunct therapyOncologyLow
- Innate immune activationImmunostimulationModerate
- Cancer immunoadjuvantOncologyLow
- Hematopoietic stimulationHematologyModerate
- ImmunostimulationImmunomodulationModerate
- HIV immunotherapyAntiviral/immunomodulationModerate
Contraindications
- Known hypersensitivity to MDP analoguesAllergy/ImmunologyHigh
- Known hypersensitivity to muramyl dipeptide derivativesAllergyHigh
- Autoimmune diseaseImmuneModerateMay worsen or interact with immune-mediated disease
- Active systemic infection with sepsis riskInfectious DiseaseHigh
- Active autoimmune diseaseAutoimmunityModerate
Adverse Effects
- Flu-like symptomsSystemic/ImmunologicalUncommon
- Flu‑like symptomsSystemicUncommon
- Injection site reactionsLocalCommon
- HeadacheNeurologicUncommonPain in the head or upper neck
- Transient feverSystemicUncommon
- FeverSystemicCommonElevated body temperature
- Cytokine releaseImmunologicalCommon
- Injection site erythemaLocalCommonRedness at the injection site
Drug Interactions
- TNF‑α inhibitorsModerate
- Immunosuppressants (e.g., cyclosporine)Moderate
- Antiretroviral therapy (e.g., zidovudine)Low
- CorticosteroidsModerate
Population Constraints
- PregnancyReproductive SafetyRelative
- Renal impairmentOrgan ImpairmentRelative
- Pediatric populationAgeRelative
- Pediatric patients (<12 y)AgeRelative
- Pregnant womenReproductiveRelative
Regulatory Status
- European UnionInvestigationalClinical trial authorization only; not marketed.
- United StatesInvestigationalInvestigational New Drug (IND) status; no FDA approval.
- United KingdomInvestigationalNo marketing authorization; used only in research.
No regulatory approval in major jurisdictions; investigated in Phase I/II trials for cancer and infectious disease prophylaxis. Development discontinued in the early 2000s.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Murabutide?
Murabutide is a synthetic muramyl dipeptide analogue that acts as an immunostimulant via NOD2 activation. It has been studied as a vaccine adjuvant and in oncology/infectious disease trials but is not approved for clinical use.
What is Murabutide used for?
Murabutide is educationally associated with: Vaccine adjuvant, Cancer adjunct therapy, Innate immune activation, Cancer immunoadjuvant, Hematopoietic stimulation, Immunostimulation, HIV immunotherapy. Educational only — not medical advice.
How is Murabutide administered?
Recorded routes of administration: Intramuscular, Intravenous, Subcutaneous.
What are the potential side effects of Murabutide?
Reported adverse effects include: Flu-like symptoms, Flu‑like symptoms, Injection site reactions, Headache, Transient fever, Fever, Cytokine release, Injection site erythema. This list is not exhaustive — consult a qualified clinician.
Who should avoid Murabutide?
Recorded contraindications: Known hypersensitivity to MDP analogues, Known hypersensitivity to muramyl dipeptide derivatives, Autoimmune disease, Active systemic infection with sepsis risk, Active autoimmune disease. Consult a qualified clinician before use.